Thursday, December 31, 2020

The Devil Went Down to Georgia

Was in the form of a Boston Globe reporter looking to steal a couple of Senate seats and something I just happened to have on my mind:

"Georgia Republicans vow to vote in January, ‘rigged system’ or not, as Democrats steel for a turnout battle; Republicans worry Trump’s claims of election fraud might keep their voters at home. Democrats aren’t counting on it" by Jess Bidgood Globe Staff, December 9, 2020

SAVANNAH, Ga. — At campaign events in Georgia in recent days, President Trump’s most committed supporters vowed to turn out anyway, suggesting his war on the system and the officials who run it may not necessarily keep them from the polls, and Democrats in the state are not counting on them staying home.

Well aware that the results will hinge on turnout, many Republicans campaigning for the two senators have been trying to thread a delicate needle: Stoking distrust of November’s results while urging — and in some cases begging — people to vote on Jan. 5 anyway.

“Don’t let anybody tell you not to go vote,” said Representative Doug Collins of Georgia, a Trump ally who spoke before Vice President Mike Pence during a Savannah rally last week, while also alluding to “problems” in the November election.

Cognitive dissonance has not been an obstacle to very much during the Trump years, and if the crowds who flocked to see Trump and Pence campaign in the state were any indication, the effort is working.

Tammy Prince, of Albany, Ga., fully believes the election disinformation she has seen on right-wing cable channels like Newsmax, but she also believes this: “We’ve still got to vote,” she said at Trump’s rally in Valdosta on Saturday night.

Democrats, who are working furiously to turn out their own voters, say they aren’t expecting the Republican infighting to depress the party’s turnout.

Runoff elections take place in Georgia if no candidate in a race gets a majority of the vote in the general election. They generally favor Republicans, who historically have turned out for runoffs at higher rates than Democrats. In 2018, Georgia’s Republican secretary of state, Brad P. Raffensperger, edged his Democratic opponent by just 0.5 percentage points in the general election but won his runoff by about 4 percentage points when turnout cratered after the midterms. Saxby Chambliss, a former Republican senator from Georgia, won his 2008 runoff by nearly 15 percentage points, five times his margin in the general election.

Republicans are no longer taking that edge for granted. They know the state’s demographics and politics have changed since then and Democrats have built a powerful voter registration and turnout machine, largely through the efforts of Black women activists.

God help you if you argue with them!

Alarm among Republicans grew last week when two Trump allies, Sidney Powell and Lin Wood, held a “stop the steal” rally outside of Atlanta. They urged the president’s supporters not to vote in the Senate runoffs, which pit Loeffler against the Rev. Raphael Warnock and Perdue against documentary filmmaker Jon Ossoff.

The party has been in damage control mode ever since, creatively finding ways to entertain the delusion that Trump actually won the election, while encouraging people to vote in a system they think was rigged.

Campaigning in Savannah, Pence suggested any problems with the November election would magically evaporate in the January voting.

At Trump’s rally at the Valdosta airport, there was an even sharper contrast between the president’s rhetoric and his dutiful efforts to get out the vote. Before the rally, the crowd milled around the tarmac below an enormous television screen urging them to sign up for absentee ballots, a form of voting Trump has railed against.

“They cheated and they rigged our presidential election,” Trump said during a 100-minute speech mostly devoted to such complaints. His supporters shouted down Loeffler and Perdue at certain points, while Trump insulted Raffensperger and the state’s Republican governor, Brian Kemp, but Trump ultimately said the magic words: “You have to get out and you have to vote.”

Kemp was sent a message when his daughter's boyfriend, who also worked for Loeffler, was killed in a flaming car wreck.

The relief among Republicans was palpable.

“He said what he needed to say,” said Brian Robinson, a Republican strategist in Georgia, but he warned that, while Loeffler and Perdue need Trump’s base to turn out for them, they also need the support of moderate Republicans who are frustrated by Trump’s damaging election claims.

I'm sure the Dominion voting machines will work this time.

Meanwhile, Democrats are seizing on Trump’s involvement in the runoffs in hopes that it will keep their own base motivated.

“The efforts to discredit our election, to overthrow the results, that’s also going to bring new voters out who understand it’s not just about two Senate seats — it’s really a referendum on Trump and those who continue to push forward his agenda, which has been riddled with misinformation,” said Nguyen.

Democrats know they go into the runoffs at a disadvantage: Ossoff was 88,000 votes behind Perdue in November’s general election, and Warnock garnered fewer votes than the combined total of Loeffler and Collins, who also ran in a multi-candidate field in that Senaterace.

They are hoping to gain votes from the 23,000 Georgians who will have turned 18 between the general election and the runoff, and Democrats see signs of promise in early absentee ballot data. So far, 71,000 people who didn’t vote in November have requested absentee ballots, and they are disproportionately young and nonwhite. About 1.6 million people already have applied for absentee ballots and voters of color are returning them at the highest rates. 

Those ballot boxes must be busting at the seams with the unabashed fraud.

There was a time that I thought it mattered, but I have to laugh now at the the thought of Republicans needing to prevail to preserve the Republic, freedom, and fair elections.

Have we ever had a fair election? Maybe George Washington, I suppose, and as for freedom and Republic, where they been?

That doesn't mean the Democrats are not batshit crazy Communists, they are, but Americans literally have a devil's choice when it comes to which strain of Zioni$m will rule.

“We’re phone banking like crazy. We’re text messaging. We’ve got mobile billboards. We’ve got radio ads. We’ve got digital advertising,” said LeWanna Heard-Tucker, the chair of the Democratic committee in Fulton County, which includes Atlanta, and they are not anticipating Republicans like Sean Polwort, who blames “deep-rooted corruption” and fraud for Trump’s loss, will help them by staying home on Jan. 5.

“I will try to be the first person in line,” Polwort, an employee of a company that makes AR-15 rifles, said at Pence’s event. “We’re scared for our country’s future.”

David Newlin, a charter boat captain who runs fishing tours off the Georgia coast, is apoplectic over the “illegal voting” he believes stole this state — and the whole election — from President Trump. 

“We are all adamant that this election has been a sham,” Newlin, 60, said, repeating the false allegations of fraud Trump himself amplified when he appeared at a rally in Georgia last weekend, but Newlin’s anger at the state’s voting apparatus doesn’t mean he won’t use that same system again on Jan. 5, the day of two runoff elections that will determine control of the Senate. 

“We will crawl to the polls if we have to, to vote for Perdue and Loeffler,” Newlin said, referencing the two Republican candidates. 

For a full month, Trump has attacked Georgia’s state Republican officials and railed against the reality — now confirmed by two separate recounts — that he lost this typically red state to Democrat Joe Biden by nearly 12,000 votes. That’s triggered a war within the party and left some Republicans worried Trump has withered his supporters’ resolve to vote for Senators David Perdue and Kelly Loeffler in the runoffs, yet Abigail Collazo, a Democratic strategist in Georgia, said, “we are acting and campaigning as though this will be a very, very close race, and every single vote will matter.”

--more--"

It's the economy, stupid: 

"Crucial Georgia Senate runoffs are shaped by economic pain" by Jess Bidgood Globe Staff, December 18, 2020

FAIRBURN, Ga. — Candice Williams felt awkward, but she pulled her car into the long line curling out from the food pantry anyway, her daughter cheerfully ensconced in her car seat in the back.

She rolled slowly past the low-slung industrial buildings on the outer edge of Atlanta, toward the empty church that was now a staging ground for a phalanx of volunteers packing food into bright purple bags. It wasn’t so long ago that she was helping others instead of asking for help, but that was before the pandemic, before she lost her job as an early childhood educator and fell six months behind on rent. Her wife still works for the Postal Service, but it’s not enough to keep the family afloat. The $1,200 stimulus check she received last spring is long gone, and her unemployment benefits have run out.

OMFG!

That's the voter the Globe found?

Democrats’ critiques of two Republican incumbents, David Perdue and Kelly Loeffler, whom Democrats have relentlessly pounded as out-of-touch millionaires profiting off average people’s pain and blocking the relief that would help them, have taken on a personal edge, since they relentlessly portray the two incumbents as self-dealing millionaires who sought to profit from the pandemic through stock trades. (Both candidates have denied wrongdoing.)

Barr memory-holed that malfea$ance, and it was Pelosi who blocked the aid because it was good politics.

“How do we wind up with two senators who saw this pandemic as an investment opportunity, while they lied to us about the risk to our health and blocked relief to ordinary people?” said Ossoff, the candidate running against Perdue, at a rally with labor leaders last week.

Republicans in the state are hoping that a stimulus bill from Washington will boost the incumbents’ standing.

“It’ll certainly shut off one line of attack, and could take some of the air out of the balloon with voters who are scared because their economic situation is in a crumbling position,” Brian Robinson, a Republican strategist in Georgia, said. 

They think that $tinking turkey is going to save them?

Democrats are vowing to keep pressing their economic case — and they have also reshaped some of their organizing efforts to account for the economic pain.

At the food drive, a group of volunteers with the New Georgia Project, a civic engagement group founded by Stacey Abrams that is credited with aiding Democratic victories in the state, handed out toys in orange bags as people drove by.

They were not urging people to vote or sign up for absentee ballots; instead, they said, they were trying to build trust in a hard-hit community. 

You know what they say: "Trust, once lost, is hard to restore."

“We definitely don’t want people going to the polls basically hungry,” said Erica Clemmons-Dean, the group’s organizing director. “They have a lot of other things on their mind.”

The families coming through the line were an embodiment of how suddenly people’s economic standing has changed.

Lori Ellis, 59, has a job at an insurance company, but she said her household had swollen from four people to nine after some of her family lost their home in the downturn.

“I have a disabled mother. A disabled husband, and a daughter whose job was cut off because of the pandemic,” Ellis said, gazing at the line stretching outside of the parking lot. “I’ve never seen Margie’s line this long.”

She was planning to vote for the Democratic candidates because she believed they had a better sense of “what the people need.”

Debra Carroll, 66, cried out in frustration when she thought about how much time had passed since the last economic relief bill. “They need to do something quick, fast, in a hurry,” she said.

UNREAL!

It was PELOSI who BLOCKED it for POLITICS, this whole fucking thing is a scam along with the BS narrative being supplied by the partisan Globe.

During the pandemic, her rent has risen, and her Social Security checks can’t cover food, personal protective equipment, and the cleaning supplies she thinks will keep her safe. She visits three different food pantries to get everything she needs.

“We need some help now,” Carroll said. “Everyone keeps saying, on down the road, on down the road, but we need it now.”

It has been only six weeks since voters went to the polls, but in that time, some key economic indicators and public health measures have worsened. The country is reporting more than 200,000 new virus infections on average each day, and in Georgia, the caseload has shot up 70 percent over the last two weeks.....

All based on the diagnosis of a PCR "test" that doesn't detect COVID-19 or infectiousness.

--more--"

Related:


The Globe did notice that death, as he was the first Black American to receive a full athletic scholarship to the University of Georgia, battled racism in the Deep South, and set a path that dozens of young athletes have followed.


The incidents are under investigation as potential hate crimes which one religious leader likened to a cross burning.


Investigators are first working to rule out any accidental causes, but they believe the fire may have been intentionally set and possibly linked to three other fires in the neighborhood in the past three weeks.


She is disavowing a photo circulating on social media of her posing with a longtime white supremacist at a recent campaign event, with less than a month to go until the runoff elections that will determine the balance of the US Senate.

Maybe the pre$$ will finally ask Warnock about his spousal and child abuse.


The number that rivals the turnout at this point in the November election and points to intense enthusiasm in a pair of races that will determine control of Congress.


Democrats must oust both Senator Kelly Loeffler and Senator David Perdue to give their party power over both houses of Congress, in addition to the White House.


The New York Times doesn't like the drumbeat of misinformation from Diamond and Silk or Mark Levin, but I'm sure they would have been fine with Tammy Bruce congratulating gay Grenell on his appointment to the Holocaust Museum board by Trump while subbing for Hannity because we all love Israel and the Jewish people -- as their channel pushes war with China over its alleged control over America.

Bah, humbug!

Lola!

It's the Globe's way of putting some English on the $camdemic:

"Pandemic prompts business travel firm Lola to pivot into expense management software; Paul English’s venture takes a major detour, but it could pay off in the long run" by Jon Chesto Globe Staff, October 28, 2020

What do you do when your company’s only market is on the brink of evaporating?

If you’re the Boston travel firm Lola.com, you adapt as quickly as you can.

On Wednesday, Lola executives Paul English and Mike Volpe will announce a new business line, dubbed Lola Spend, that will offer chief financial officers and other bean counters a way to monitor and control nearly every form of corporate spending. Previously, Lola was entirely focused on helping employers manage corporate travel purchases and expenses.

It’s a good example of the Pandemic Pivot: Businesses of all sizes are rethinking their strategies right now in light of the seismic shifts in consumer and business behaviors brought about by COVID-19.

For Lola, the shift happened almost overnight, as English and Volpe tell it. In early March, Lola noticed a modest softening in US business travel, but within a week’s time, the situation worsened drastically. Concerns about the virus prompted them to tell employees to work from home, and then the travel slowdown cascaded into an outright collapse. Volpe, the chief executive, said the firm had to lay off 30 of its 100 or so workers.

Meanwhile, they decided to dust off an idea hatched the prior summer that became Spend, and put half of Lola’s engineering team to work on it.

Lola is fortunate to have a cushion of venture capital funds; it raised $37 million just last year, in a round led by VC firms General Catalyst and Accel.

Volpe said Lola Spend could eliminate the need for expense reports, as expenses are handled by Lola in real-time through the Lola app. Because transactions are made on a company card, there’s no need to reimburse the employee. For expenses over $75, the user just uploads a photo of the receipt on the spot to provide the necessary documentation required.

“It’s not a five-percent better version of Concur,” said Volpe, referring to one popular example of expense management software. “It’s a completely different way to think about the problem.”

He said Lola would have eventually developed this product, but before the pandemic, travel revenue was rising rapidly, so there was no urgency.

“With all the pivots I’ve done in my career, there’s always questions about, are we moving fast enough, [or] are we moving too fast?,” said English, the cofounder of Lola and its chief technology officer, and who previously co-founded the consumer travel firm Kayak.com.

As far as English is concerned, you can never pivot too quickly. “You need to put more resources on it than you think,” English said. “Change is hard.”

The most effective pivots, English said, are ones that keep you close to your original core strengths. In this case, Lola is dealing with essentially the same contact people in its primary target market — namely, finance officers at companies with 50 to 500 employees.

“Listen to your customers,” Volpe said. “They can point you in the direction of new problems you can solve.”

Another Boston-area travel-tech firm is also branching out because of the pandemic. Tripadvisor, the operator of consumer-focused travel websites, said on Tuesday it has developed two new revenue potential sources. Kanika Soni, the Needham company’s chief commercial officer, said the new ideas came from examining the most important needs for hotels struggling during the pandemic.

Tripadvisor will now offer a business intelligence software called Spotlight that will help hoteliers predict occupancy rates, and Reputation Pro, which will send review requests to travelers on a hotel’s behalf, for multiple platforms.

For Lola, the pivot opens up a much broader potential market, while it continues its corporate travel business with the hope for an eventual recovery. Many companies have minimal travel budgets, but most have some sort of expense account to track.

“We wanted to … use this as an opportunity rather than just trying to hide,” Volpe said. “The pandemic pushed us to do this sooner and faster.”

--more--"

One of the catalysts:

"General Catalyst-backed SPAC files for a $500 million IPO" by Anissa Gardizy Globe Correspondent, October 27, 2020

The Cambridge-based venture capital powerhouse General Catalyst — which has backed notable tech names such as HubSpot, Instacart, and Venmo — is taking a dip into a new kind of investment vehicle that’s become popular on Wall Street.

General Catalyst is the sponsoring firm behind a special purpose acquisition company, or SPAC, named Health Assurance Acquisition Corp., that plans to raise $500 million in an initial public offering, according to documents filed with the Securities and Exchange Commission on Monday. Health Assurance plans to invest the proceeds in companies at the intersection of health care and technology; however, General Catalyst is pursuing a slightly different style of SPAC listing, known as a “Stakeholder Aligned Initial Listing,” in which it will take a smaller stake in exchange for other investors agreeing to buy into a long-term strategy for Health Assurance. So instead of owning 20 percent of the company, as is typical in SPACs, General Catalyst would hold a 5 percent stake. The Health Assurance IPO would also have fewer investors overall in order to ensure all the shareholders are behind those long-term goals.

General Catalyst said it’s also set up so that initial investors do not see profits until after outside shareholders.

“Our economics are contingent upon sustained performance,” the firm wrote in its filing. “Our initial stockholders will not earn returns on their alignment shares until our other stockholders do.”

The offering expects to sell 50 million securities at $10 each.

Health Assurance Acquisition said it believes “health care is at the beginning of its Internet moment,” and it wants to power the next wave of “consumer-centric, data-driven, cloud-based health care” companies. Like other SPACs, Health Assurance Acquisition’s goal is to use the money raised in an IPO to acquire an existing company.

As a model for the type of businesses its wants to target, Health Assurance points to Palo Alto-based health care startup Livongo Health, which was just purchased by the telemedicine company Teladoc Health for $18.5 billion. Livongo was started in 2014 to help people with diabetes better manage their condition, giving them access to real-time data about their insulin levels.

Much of Health Assurance Acquisition’s management team hails from Livongo.

General Catalyst managing director Hemant Taneja, who was the lead investor in Livongo, will serve as chief executive and chairman of Health Assurance. He will be joined by Livongo’s founder and executive chairman Glen Tullman, as well as its president Jennifer Schneider.

“We want to create the conditions for 1,000 Livongos to bloom,” the company wrote, adding that General Catalyst already backs these types of companies. “We believe there will be dozens of multibillion-dollar winners created by this sectoral shift, and HAAC has a set of core beliefs and values that will help to identify the best health assurance businesses.”

--more--"

Related:


It’s really on them to learn, and hospice nurse Deborah Carlson had been hesitant to embrace the artificial intelligence tool her health system introduced earlier this year before it correctly predicted the death of a patient she thought seemed stable.

One is will doctors and physicians even be needed, and don't forget to say aaaah to the camera.

The Globe says it is imperative to look beyond COVID and the election and up towards the WellSky as some biotechs are cramming multiple fundraising rounds into a single year and have more funding than they need as Massachusetts is again ranked at the top for tech and innovation.

As global access widens, the hopes of humanity are grabbing all the loot they can as the merger comes at a boom time for classic toymakers, as parents turn to familiar products to entertain kids stuck in lockdown once the Salt Lake Tribune stops printing a daily edition, ending a nearly 150-year run of a daily newspaper deliveries in an all-stock deal that will combine the two Silicon Valley chip makers.

Expect virus cases to grow until P&G’s new cleaning product arrives. It is a spray that was approved by the US Environmental Protection Agency as effective in killing the virus that causes COVID-19.

For Auld Lang Syne: Epipen $mudge

Happened on Obama's watch:

"US taxpayers may have overpaid for Mylan NV’s EpiPen shot by as much as $1.27 billion over the last decade, according to a US government report. Senator Charles Grassley, an Iowa Republican, on Wednesday posted a copy of a report by the Department of Health and Human Services’ Office of the Inspector General. The report says that Mylan, by classifying EpiPen as a generic drug rather than a brand-name product, shortchanged the Medicaid program for the poor. Under Medicaid, makers of brand-name drugs must provide deep discounts on their products. In October, Mylan said it reached a settlement with the US to pay $465 million for misclassifying the drug as a generic product, which doesn’t require the same discounts. Grassley has been critical of the October settlement, calling it too small."

They were probed over cost of EpiPen shots, but with no competition the prices soared and they paled in comparison to huge increases that Mylan Laboratories took on dozens of other medicines that may have violated antitrust laws-- “it’s like the bank robber saying ‘Don’t worry, we don’t rob banks anymore” -- as the hands of Hillary Clinton scrubbed clean.

Mylan won either way:

"How the generic EpiPen could actually be more profitable for Mylan" by Damian Garde, August 29, 2016

In the latest twist on the EpiPen saga, drug maker Mylan appears to have figured out a way to make more money on the product — while chopping the price in half.

Mylan’s new plan is to sell a generic version of its EpiPen directly to consumers, in what CEO Heather Bresch called an “extraordinary commercial response.” The new product, expected in the coming weeks, will be identical to EpiPen except for the label, and will sell for $300 for a two-pack — about half the cost of the EpiPen.

Here’s what we know about the move:

Why would Mylan do this?

The tactic might help quell a bit of the public furor over rising EpiPen costs.

It could also be a savvy business move.

Last week, Bresch took pains to explain that Mylan actually makes just $274 from each $608 pack of EpiPens it sells, because the product winds through a long line of middlemen before reaching the consumer.

Cutting out the middlemen to sell directly to patients means that Mylan can pocket the full $300 price — and may actually make as much as $26 more on the generic for every unit it sells, depending on the cost of shipping and manufacturing.

Even if Mylan does send some generics through the traditional supply chain, the move will help it box out competition from other generic drug makers, and the lower cost could boost sales, as patients who limited their EpiPen purchases because of the high cost might feel more comfortable buying another kit to have on hand in case of emergency.

Does it make a difference for patients?

Arguably.

How will this affect competition?

Here’s where it gets interesting.

Can you just launch a generic without FDA approval?

You can if it’s identical.

Does this mean Mylan’s in the clear?

Probably not....

--more--"

Just one more way to game the system, along with the stealth ad campaigns and shell game at everyone's expense:

"EpiPen maker games the system, at everyone’s expense "August 24, 2016

The spiraling price of the EpiPen injector — a staple of backpacks and school nurses’ offices everywhere — is only the latest version of a destructive story: A drug company scoops up the rights to a medicine that’s been around for years, concocts an aggressive new business plan, and inflates the price by an obscene amount. Remember Martin Shkreli, who increased by 5,000 percent the cost of a 62-year-old pill to treat parasitic infections?

Yes, I do remember him, do you?

The recent $100 price hike for the EpiPen, a device that conveniently delivers the drug epinephrine to counteract severe allergic reactions, isn’t quite as steep. But the basic strategy is just as shameless.

The patent holder Mylan, which acquired the rights to EpiPen from Merck KGaA in 2007, isn’t using its new revenues to invent new ways of saving lives. The device isn’t getting any harder to manufacture. The epinephrine inside it only costs about $1. The company is just padding its margins by gaming the insurance system and exploiting other inefficiencies in US health care — at the expense of patients and everyone else who pays health care premiums.

Developing a new drug or device requires exhausting research and hundreds of millions of dollars, with slim odds of success in the end. It’s simpler to purchase an existing product, generate more volume through slick marketing, and then squeeze more money out of customers. In real dollars, the EpiPen’s price has risen by about 450 percent since 2004, to $600 or more for a pack of two.

For those allergic to bee stings or certain foods, the EpiPen can be a lifesaver. That makes it an easy sell. It lands on many back-to-school shopping lists, and it’s pitched as “the brand more school nurses have been trained on and taught to administer.” Mylan sold 3.6 million EpiPens in 2015, reaping more than $1 billion, and it will likely unload at least that many this year — the injectors are supposed to be replaced every 12 months.

Mylan lucked out last fall when global drug giant Sanofi had to recall its competing device, and again when the Food and Drug Administration rejected a generic version of the EpiPen. In general, the FDA’s progress in reviewing generic drugs has been slow — a boon to patent holders like Mylan, because long regulatory delays discourage companies from trying to bring new generics to market. The lack of competition has allowed Mylan to raise the EpiPen’s price repeatedly, with no repercussions.

The company also has used the impenetrable health insurance system to disguise the EpiPen’s actual cost. In a statement in response to mounting criticism, Mylan said this week that “nearly 80 percent of commercially insured patients” who used a company-supplied copay coupon last year received an EpiPen “for $0,” but it’s a deceptive deal, as insurers still pass on the costs through more expensive premiums for all.

If nothing else, Mylan’s scheme becomes harder to conceal as more Americans shift to plans with big deductibles and copays. In the long term, the Affordable Care Act should reduce the perverse incentives within the insurance system — if Congress builds on the law’s reforms, rather than whittling them down. Lawmakers can also help the situation by giving the FDA the direction and the funding necessary to speed up the introduction of generic drugs of all sorts.

In the short term, Mylan needs to hear from angry consumers and from the pols who represent them. As it happens, Mylan’s chief executive, Heather Bresch, is the daughter of Senator Joe Manchin of West Virginia, but that shouldn’t get the company off the hook. Senator Amy Klobuchar, a Minnesota Democrat, wants a Federal Trade Commission investigation into the EpiPen episode. Senator Chuck Grassley of Iowa is demanding that the company explain its actions. In the court of public opinion, “we did it because we could” just doesn’t cut it.

--more--"

"The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes" by Damian Garde, August 24, 2016

Drug company CEO Heather Bresch affectionately describes the humble EpiPen as her “baby,” a once-middling product that she turned into a blockbuster.

With aggressive advertising — and even more aggressive price hikes — Bresch has fostered the EpiPen into a bestseller that brings in more than $1 billion a year in revenue for Mylan Pharmaceuticals, but the growing furor over drug pricing threatens to turn Mylan’s biggest asset into a liability, and it has forced Bresch into an unwelcome spotlight, as anxiety over the rising cost of medicine has drug industry critics seeking out the next Martin Shkreli.

In the past week, Mylan has faced public scorn, investor skepticism, and castigation from a group of senators calling for an investigation into why EpiPen’s cost has soared fivefold under Bresch’s watch. Even Shkreli, widely perceived as a paragon of greed after hiking a drug price by 5,000 percent, decried Mylan as a group of “vultures.”

The EpiPen, an auto-injector used to reverse life-threatening allergic reactions, is inextricably tied to Bresch, whose ascension at the company tracks with the product’s rapid growth. 

The reason the product is needed is because of the multitude of vaccinations kids are subjected to these days. The allergies come from the adjuvants they contain to get your body to accept the needed poisons.

At 47, Bresch has spent most of her life at Mylan, working her way up from a secretarial desk in the basement of what was then a small West Virginia firm. In the ensuing years, Bresch has overcome an academic scandal, hostile takeover attempts, and questions about her true control over Mylan.
Subscribe to The Readout: A guide to what's new in biotech

She has also become one of the drug industry’s highest-paid CEOs, pocketing more than $18 million in cash and stock last year, and sitting at the head of a $26 billion enterprise.

Now, as the specter of a Senate investigation looms, Bresch faces what could become her biggest challenge. And, befitting her uncommon career, it comes with a twist: Among the Senate’s membership is her father, Joe Manchin, a populist West Virginia Democrat whose influence is woven throughout her rise in the drug industry.

Bresch first adopted EpiPen in 2007, when Mylan purchased the generic drugs division of Germany’s Merck KGaA for $6.7 billion. It was a milestone for the growing company, and then-CEO Robert Coury appointed Bresch to sort out the integration.

EpiPen was one of about 400 products that Mylan acquired in the deal, and it was unremarkable in business terms: a plastic device that, with the push of a button, injected what Bloomberg has estimated to be about a dollar’s worth of the generic hormone epinephrine to treat deadly anaphylactic shock. It sold for about $57 and made just $200 million a year for Merck KGaA, accounting for less than 5 percent of the company’s generics revenue at the time.

Bresch saw potential in the decades-old auto-injector, and Mylan credits her with spearheading an effort to widen its use, but her drive to make the EpiPen a top seller was almost derailed before it started.

Bresch was promoted to chief operating officer at Mylan shortly after the deal with Merck KGaA. The official corporate announcement touted her MBA from West Virginia University. Months later, an exhaustive investigation by the Pittsburgh Post-Gazette revealed that she hadn’t finished the MBA program — and a later independent report found that university officials had falsified her transcripts to conceal that fact, adding in grades “pulled from thin air.”

Looks CRIMINAL to me.

The scandal shined a light on Bresch’s status as a member of coal country royalty. Her father, Manchin, was then West Virginia’s governor, and the university’s leadership included longtime family friends and Mylan insiders.

Bresch held onto her job at Mylan, maintaining that she had done everything she needed to do to earn that MBA. Neither she nor her father was accused of wrongdoing, but the episode reeked of cronyism and sparked a faculty protest. WVU’s provost and business school dean later resigned, and the university revoked Bresch’s degree.

Both Bresch and Mylan declined to comment. Manchin’s office didn’t return voicemails left Tuesday.

He is still a senator.

While the affair was embarrassing for the university, it had little effect on Bresch’s career.

Bresch soon became Mylan’s president and began a crusade to expand the availability of EpiPens. Drawing on her experience as Mylan’s former director of government relations, Bresch led a lobbying campaign to spread the word about the risks of anaphylaxis and the efficacy of EpiPen.

Mylan scored a coup in 2013 with the adoption of the School Access to Emergency Epinephrine Act, which gave preferential federal treatment to schools with EpiPen stockpiles. Sales increased, and Mylan raised the price of its banner product each year.

In 2011, Coury surprised Wall Street by announcing that he’d step down from the CEO role at year’s end, leaving Bresch as his anointed successor. It was to be a major culture shift for Mylan, which had become synonymous with Coury’s blunt, often profane way of conducting business. Bresch, with her lilting West Virginia accent and political savvy, presented a new way forward for a company that had underperformed in the eyes of many analysts, but Coury never really went away, instead taking on the title of executive chairman, and in the years since Bresch became CEO, it has often been unclear just who is pulling the strings at Mylan.

Last year, when Israeli drug maker Teva Pharmaceutical mounted a hostile takeover attempt, it was Coury who acted as Mylan’s mouthpiece, baiting the other company’s management team and penning a searing 3,000-word letter to its board. At the same time, he starred in Mylan’s failed attempt to acquire rival generics firm Perrigo, sparking a bitter public feud with that company’s CEO before eventually admitting defeat.

They helped block a Congre$$ional probe, and would it make you feel better if you knew they were in league with Pfizer and Moderna?

Maybe you should have a smoke and think about it.

In Mylan’s last annual report, the opening note to shareholders is signed by both Coury and Bresch, and letters to the company end up at the Robert J. Coury Global Center, a 280,000-square-foot Pittsburgh outpost christened in 2013, but Bresch was front and center for Mylan’s most recent controversy, a politically sticky situation that again looped in her father.

In 2015, Mylan announced that it would move some of its operations overseas in search of a more favorable tax rate. The tactic, known as an inversion, exploits what President Obama has called “one of the most insidious tax loopholes out there.” For Mylan, inversion meant shifting its business address to the Netherlands through a complicated transaction with Abbott Laboratories.

Manchin, who learned of the move only on its official announcement, told The National Journal that what his daughter did ought to be illegal. (He later gave a statement to The New York Times saying Mylan’s move was “systemic of a larger problem with our corporate tax code that puts American companies at a disadvantage with their global competitors.”)

This put Bresch in an awkward spot. Mylan had long painted itself as a different sort of drug company, one principally concerned with stakeholders — like patients and employees — rather than the short-term profits of shareholders and investment banks, and Bresch had once been hailed by Esquire as a “patriot of the year” for her work to improve safety standards for generic drugs.

So why was her company leaving home in the name of corporate profits?

Bresch’s spin: Mylan needed to ditch the United States to stay in the US. Setting up shop in the Netherlands provided tax savings, sure, but it also gave Mylan the protection of Dutch law, which makes it easier for companies to fend off hostile acquisitions. At the time, Teva was trying to galvanize a shareholder revolt to depose Mylan’s management, something Bresch said could have imperiled patients and employees. 

I'm convulsing at the sophistry!

“I said, ‘You know, Dad, we have 5,000 employees in Morgantown, W.Va. — we’re one of the largest employers in West Virginia,’” she told an audience at Fortune’s Most Powerful Women Summit in 2015. “I can guarantee you, if we don’t protect ourselves, no one’s going to protect those jobs.”

Explaining EpiPen’s 450 percent price increase may prove more difficult, as the public outrage that once dogged Shkreli’s Turing Pharmaceuticals has shifted to Mylan.

Senator Amy Klobuchar (D-Minn.) has called for the Federal Trade Commission to investigate Mylan’s pricing practices, writing Monday that “not only is this alarming price increase unjustified; it puts lifesaving treatment out of reach to the consumers who need it most.” The same day, Senator Chuck Grassley (R-Iowa) wrote Mylan asking for information on how it set the price for its auto-injector, and Senator Richard Blumenthal (D-Conn.) called for the company to lower the cost of EpiPen.

Days before, Senator Bernie Sanders had tweeted that “there’s no reason an EpiPen, which costs Mylan just a few dollars to make, should cost families more than $600.” A MoveOn.org petition, titled Stop Immoral Price Gouging for Life-Saving EpiPen, had garnered nearly 19,000 signatures as of Tuesday night.

In a statement, Mylan defended its patient-access programs, which it said provide EpiPens for free to 80 percent of insured patients, but the company did not address price increases or their effect on patients without insurance.

Meanwhile, some shareholders are losing faith. The company’s stock price has fallen more than 30 percent since last summer, when Mylan finally shook off the threat of a takeover by Teva. In May, Goldman Sachs downgraded Mylan, citing a “cloud over generic drug pricing,” and on Tuesday, analysts from Citigroup warned that the current public focus on EpiPen pricing could weigh down Mylan’s stock, especially if the company has to appear before a Senate committee.

If Mylan loses too much value, it could struggle to defend itself from a future hostile takeover, but Bresch herself is well-insured: According to a recent analysis from Bloomberg, if she’s deposed in a merger, she’s in line for a $61.5 million golden parachute.

Time to bail out!

--more--"

Related:

Mylan CEO to appear before congressional committee on EipPen price hikes

She was rather quiet as she defending the pricing (so that is what $cum looks like) and lied about profits (I'm sorry, she was ‘‘intellectually dishonest’’ in her testimony, and isn't that lying to Congre$$ and a crime)?

"Heather Bresch was beaten up by Congress last week — and rightfully so. The Mylan Pharmaceuticals chief executive testified before a House committee investigating EpiPen price hikes, and her performance was largely dreadful. Although soft-spoken and respectful, she often dodged questions, and too many of the answers she did give were vague or hard to follow; nonetheless, the hearing may yet prove beneficial. Sadly, none of the committee members seemed prepared to press Bresch on the fine points of her pricing strategies, and that was a missed opportunity. “No one followed up, because everybody wants a show with grandstanding and finger pointing. So we didn’t come away with much insight,” said Pratap Khedkar, a managing principal at ZS Associates, a consulting firm to drug makers. So how could all that posturing actually be helpful? I say this because the committee reiterated its demand that Mylan fork over documents...."

She even lied about the price reduction as they continued to overcharged for the EpiPen after paying a $465m settlement to Medicaid and moved past the controversy to continue feasting at the public trough with a well-honed penchant for brazen envelope-pushing despite receiving repeated warnings from federal officials and possible violations of antitrust laws for exploiting taxpayers to the detriment of society at large and predilection for unfairly boosting its profits (it accounts for about 40 percent of Mylan’s operating profits) before blowing off the Senate. 

After slashing prices (it still costs less than $10 to make one), some devices had to be recalled so her pay package was cut and House Democrats began a probe after a member got sick off a salad bought at Logan Airport before his Delta flight out of Bo$ton.

Also see:

The an$wer to anything and everything is a PR campaign.

Yeah, go fly a Kite.

Not even the lawsuits can slow them down.


They were working on a vaccine, if you can believe it.

"Mylan misled investors over EpiPen pricing probe, SEC says" by Riley Griffin and Matt Robinson Bloomberg News, September 27, 2019

Mylan NV misled investors for at least a year about a Justice Department investigation into the allergy shot EpiPen that would eventually cost the company nearly $500 million, the US Securities and Exchange Commission said Friday.

Under the agreement with the SEC, first disclosed as a settlement in principle by Mylan in July, the drugmaker will pay $30 million.

The settlement appears to close one part of a long-running saga over a product that boosted Mylan’s sales but also brought controversy.

The SEC lawsuit details years of Mylan’s efforts to fight allegations it overcharged taxpayers, and then negotiating with the government over a settlement. Neither the investigation nor the potential settlement was disclosed to investors while those events were ongoing. The company in October 2016 announced a settlement with the Justice Department for $465 million.

“Investors were kept in the dark about Mylan’s EpiPen misclassification and the potential loss Mylan faced as a result of the pending investigations,” said Antonia Chion, associate director of the SEC’s Division of Enforcement.

The SEC settlement is the latest black eye for a company that’s no stranger to controversy.

EpiPen, the company’s best-selling product in recent years, attracted attention after the drugmaker raised the price for a two-pack of the pens to about $600. The company has also been dealing with supply shortages of the product, which is manufactured by a division of Pfizer, while also facing new competition from copycat products.

When selling the EpiPen to Medicaid, Mylan was required to rebate a portion of the sales to the government. By classifying EpiPen as a generic drug, Mylan paid much lower rebates, the agency said.

Mylan has been named in lawsuits by state attorneys general that accuse 20 drugmakers of conspiring to carve up the market and raise price on more than 100 generic drugs. Democratic members of Congress have said the company has stonewalled their inquiries into its conduct.

Mylan has said that it acted properly and that its executives did not conspire to fix prices. It has also said that it is cooperating with investigations. Pfizer and Mylan in July struck a deal to combine Mylan and Pfizer’s older-drugs business.

The EpiPen settlement relates to a complex program in Medicaid, the federal-state health program for low-income people, that’s meant to get the government deep discounts on drugs. Under the program, almost all drugs are subject to rebates to the government, but generics, which are typically lower-priced and have slim margins, pay a much smaller rebate than brand-name products.

Even though EpiPen faced little competition and the company had increased the price by hundreds of dollars, it had been classified as a generic product under the discount program. In 2013, the Centers for Medicare and Medicaid Services told Mylan that Epipen “has an incorrect drug category” in a government database, and that the company needed to verify and update the information.

Mylan’s justification for calling EpiPen a generic product was a 1997 letter from the government, but inside the company, executives raised doubts about whether the letter was sufficient, according to the SEC. The 1997 letter was “basically just done as a result of a conversation two guys who were there at the time had,” one Mylan executive said in an internal email, according to the SEC lawsuit. If there had been a new review, “they would have been denied given today’s market size and that ours was a loose interpretation to begin with,” said the executive.

In November 2014, the SEC said, Mylan received the first Justice Department subpoena as part of a civil investigation into whether the company had misclassified the drug and cost taxpayers millions of dollars. At the time, about 20 percent of EpiPen’s $1 billion in annual sales came from Medicaid, according to the SEC.

For the next year, Mylan argued that the government should drop its investigation. In response, the government sent more subpoenas, and had the company to sign an agreement extending the statute of limitations. In October 2015, however, Mylan began to share estimates of potential damages with the Justice Department, saying that in one quarter in 2015, calling EpiPen a generic had let the company avoid somewhere between $12 million and $42 million in rebates to Medicaid.

In 2014 and 2015, Mylan told investors in filings that it was discussing the matter with the Centers for Medicare and Medicaid Services, but the SEC said that the company misrepresented the government’s position, downplaying its risk.

Mylan said that it believes the SEC settlement is the right course of action. “The company continues to be committed to the highest levels of integrity with respect to all aspects of its business operations,“ it said in a statement.

--more--"

Time to vape some herb despite the advice of Sharon Levy, among others.

For Auld Lang Syne: Diamond DUST

A few sprinklings for you this New Year's Eve:

"Startup uses diamond dust to root out bogus products" by Hiawatha Bray Globe Staff, August 12, 2019

There are a lot of counterfeit products out there — bogus designer clothing, fake auto parts, even phony aircraft components, but a Framingham company thinks it can put the forgers out of business, with a spray of artificial diamond dust.

DUST Identity spun off from the Massachusetts Institute of Technology in 2011, and has received more than $2 million in federal grants through the Defense Advanced Research Projects Agency. In its early days, the company focused on futuristic ideas, like using nanoparticles of synthetic diamond to build chips for quantum computers that haven’t been developed yet, ut now the company wants to use its diamond particles to weed out counterfeit products, which cost the US economy $600 billion a year, according to the FBI.

DUST Identity recently raised $10 million in venture funding, in a round that included venture capital firm Kleiner Perkins and the investment arms of aerospace companies Airbus and Lockheed Martin, companies that are always on the lookout for better ways to identify and track the millions of parts they purchase every year.

DUST Identity’s chief executive and co-founder Ophir Gaathon, said his company is getting inquiries from carmakers, pharmaceutical firms, even food and cosmetics companies.

“We’ve just been overwhelmed with the number of requests,” said Gaathon, “I think we’ve hit a nerve.”

DUST stands for “Diamond Unclonable Security Tag.” The system combines tiny diamond particles with a polymer that bonds the diamonds to the surface of a manufactured object. The system is compatible with a variety of polymer chemicals, so a manufacturer can use whichever chemical works best for its products.

“We see this technology as rather compelling,” said Chris Moran, general manager of Lockheed Martin Ventures. His parent company makes some of the US military’s most important aircraft, including the F-35, F-22 and F-16 fighters, but even for these highly specialized airplanes, he said, “there are potentially lots of counterfeit parts on the market.” So Lockheed Martin has begun testing the DUST Identity system for its most critical “Class I” parts.

Thomas d’Halluin, managing partner of Airbus Ventures, said that Airbus is also trying out the DUST Identity system. “The probability of counterfeit parts is a real threat,” d’Halluin said. “There is no room to negotiate with the safety of our products.”

--more--"

Related:


They made Airbus adjust to a changing market, and aerospace still very much a man’s world.

"‘That’s going to be a huge savings’: Raytheon to reduce office space by up to 25 percent" by Anissa Gardizy Globe Correspondent, October 27, 2020

Raytheon Technologies Corp. is realizing it doesn’t need all of its 31 million square feet in office space anymore.

Chief executive Greg Hayes, said on an earnings call Tuesday that he envisions “the office of the future” to be a mix between in-person and remote work.

Raytheon had already been aiming to reduce its costs this year by $2 billion and to conserve $4 billion in cash as part of its April merger with United Technologies Corp., and to adjust to the pandemic’s hit on commercial air travel. So far, the company has trimmed its workforce by about 20,000 people.

Now, Raytheon is looking to double down on reducing its office footprint as the ongoing pandemic proves employees can do their jobs from home.

“Our original goal was to reduce and consolidate office space by about 10 percent, or about 3 million square feet,” Hayes said on the call. “I now think we could see upwards of 20 percent to 25 percent reduction in square footage. That’s going to be a huge savings.”

The reduction could amount to about three-and-a-half times the size of the Boston Common, but the local impact is muted because the company has relatively little office space in Massachusetts.

Hayes said it became apparent to him that Raytheon didn’t need all of its physical space as he toured the country, visiting facilities where “literally a handful of folks” were working in-person and the rest were “being efficient working remotely.”

“I think the ability to work remotely with the technology that we have, without losing productivity, is essential in our go-forward plan,” he said. “That’s easy cost savings in my mind."

Raytheon’s stock tumbled after a third-quarter sales decline in the company’s defense divisions exacerbated a deep slump in its commercial aerospace business.

Revenue slipped 2.3 percent in the missile and defense unit and posted a similar drop in the intelligence and space operation, Raytheon said Tuesday. That crimped the divisions' role as counterweights to Raytheon’s commercial jet engines, electronics systems, and spare parts, which have been slammed by the pandemic. The results underscored the uncertain outlook for Raytheon amid an unprecedented collapse in demand for air travel.

Raytheon stock plunged 7 percent to $56.53 at the close of trading Tuesday.

--more--''

It's a cutthroat indu$try:

"Coronavirus opens a stark divide in aerospace industry" by Aaron Gregg The Washington Post, November 3, 2020

Third-quarter financial earnings reported in recent weeks reveal a stark economic divide in America’s aerospace industry, an export-rich sector that employs hundreds of thousands of manufacturing workers across all 50 states.

The economic crisis caused by the coronavirus has elevated those who build jets, missiles and other advanced weaponry for the US military and its allies, but companies involved in commercial aircraft production have seen their finances wrecked by a persistent global slowdown in air travel.

Analysts said the divide illustrates how the coronavirus has created unexpected winners and losers throughout the economy.

“Companies that are largely in the defense business are doing just fine ... the impact of COVID-19 on their operations has been minimal,” said Ron Epstein, managing director for aerospace and defense at Bank of America Merrill Lynch Global Research.

Companies that make or contribute to the production of commercial jets have been forced to make tough choices as airline demand for new jets has collapsed. And the workforce has often borne the brunt of it.

Waltham, Mass.-based manufacturer Raytheon Technologies has laid off almost 20,000 people who worked primarily in the company's engine and aircraft parts divisions, executives said. The staff reductions account for about a fifth of the company's commercial workforce, which it only recently obtained through a massive merger with a company previously known as United Technologies.

Collins Aerospace, an aircraft parts manufacturer that Raytheon acquired in the deal, reported a 34 percent drop in sales in the third quarter of 2020 compared to last year. Pratt & Whitney, a Connecticut-based jet engine manufacturer acquired in the same transaction, also lost about a third of its sales.

Raytheon chief executive Greg Hayes told investors the staff reductions were “difficult but necessary,” adding that the company is planning for “a long, slow recovery.”

"The fact is we don't think you're going to see return to normalcy until probably mid-2023 at the earliest," Hayes said.

XXXX

The recovery "is clearly not a V," Hayes said, referring to a quick bounce-back that many had hoped would follow the economic crisis.

Few in the industry have been hit harder than Boeing, the beleaguered Chicago-based jet manufacturer. Boeing entered the crisis in a weak position because its flagship 737 Max jet was grounded due to equipment problems. The Max still has not been cleared to fly.

Boeing has kept its head above water only by loading itself up with debt, and carrying out aggressive restructuring efforts to prepare for years of depressed sales.

Then they are GOING DOWN as American Airlines is expanding pre-flight virus testing to domestic flights!

In early May it raised $25 billion in a corporate bond sale, making its debt comparable to that of some small sovereign nations like New Zealand and Iceland. It started another bond sale Thursday that should free up even more cash.

It has also carried out aggressive staff cuts, redirecting entire product lines to conserve resources.

Boeing announced last Wednesday it will cut its global workforce to 130,000 by the end of 2021; it started 2020 with 160,000. The cutbacks will have a particular effect in Everett, Wash., north of Seattle, which faces steep cutbacks related to production of the 787 Dreamliner. That production line is being consolidated at a nonunion factory in South Carolina.

Companies that get a majority of their revenue from government contracts ― General Dynamics, Lockheed Martin, and Northrop Grumman in particular ― are doing well by comparison.

“At least COVID-wise, the defense industrial base has been somewhat of a haven from the storms that are buffeting the economy,” said Wes Hallman, vice president at the National Defense Industrial Association. 

All you got was $600 of your own money, taxpayer.

Despite the operational disruption the pandemic caused to their government customers, those companies benefited from an early declaration that businesses involved in national security should be declared essential. They were also helped by improved financing terms that the Pentagon approved early on in the crisis, and bailout funding that was directed at some of their suppliers.

I was told it was a good investment even if they wasted it.

General Dynamics, which specializes in military weaponry including tanks and nuclear submarines but also owns the Gulfstream business jet manufacturer, saw a modest increase in revenue over the previous quarter. Gulfstream actually sold more jets in the most recent quarter than Boeing did, a mark of how the pandemic has altered the playing field.

The subs are turkeys!

Northrop Grumman saw a 7 percent increase in the most recent quarter despite over $800 million in COVID-related costs. The growth was driven in large part by new business in the company’s space systems division. It secured a leadership role in an $85 billion program to rebuild the nation’s intercontinental ballistic missiles.

Lockheed Martin, the world’s largest defense contractor and the maker of the F-35 Joint Strike Fighter, had its best quarter ever. It reported record sales of $16.5 billion, representing an 8.7 percent increase over the previous quarter.

Things are going so well at Lockheed that the company was able to “accelerate” roughly $1.8 billion to its suppliers. It also increased its quarterly dividend by about 8.6 percent.

George Ferguson, an aerospace analyst with Bloomberg, said the recent results also show how some companies may have over-invested in commercial aircraft before the crisis.

“With every economic expansion, management teams sort of lose their minds,” Ferguson said. “You get to the end of the expansion and commercial is rising so fast that they’d like to put all of their business there, and then you’re reminded that air travel can stop on a dime.”

It's never meant to take off again, either.

--more--"

Wednesday, December 30, 2020

Clean Plate

Just picking at what the Globe has to offer, and with each passing day I find myself with less of an appetite:


It's 1,000 COVID-19 deaths as Massachusetts has suffered some of the highest death rates in the country from the coronavirus, partly because a wave of infections tore through nursing homes across the state early in the pandemic.

I would just like to note that the wave of infections in nursing homes was because the criminal tyrant, 'er, governor, who was on TV as I was typing, sent sick people there.

Speaking or criminal chief executives (or soon to be anyway):


With the pace of the COVID-19 vaccination rollout lagging the timetable US and Massachusetts officials laid out only weeks ago, some prominent public health leaders are criticizing what they say is poor planning and a lack of urgency by government leaders. 

That's government all over and sure doesn't assure one regarding the product; however, I've learned to take the dekes and deceptions of my agenda-pu$hing pre$$ with a grain of salt. They want us to relax and breathes would a boa constrictor.

(below fold)


He is under pressure to act and the move was just the beginning of a saga that is likely to engulf the Senate for the rest of the week, according to the Wa$hington Compo$t, so I will leave that for another day even as it boosts Biden and shows a potential path for his agenda in Congress, which will give him some breathing room when he enters the White House next month, according to Carl Hulse of the New York Times.


He is in line to become Massachusetts Speaker of the House after DeLeo announced his resignation, although there is a dark-horse candidate who could pull an upset.

The Globe says Beacon Hill needs to get its act together and pass the economic development bill on this, the 50th anniversary of the EPA.


The Globe already got mine, but there are a few rules you must abide by (of course) before you’re allowed the privilege of letting them devour your tree at a handful of farms around Massachusetts.

{@@##$$%%^^&&}

The page A2 lead:

"Biden said he would invoke the Defense Production Act to ramp up production of coronavirus vaccines. The law, enacted in 1950, gives the president the power to compel companies to produce and distribute supplies. Biden said Trump’s vaccine distribution efforts were falling far behind what had been promised and said he would ’'move heaven and earth’' to bring an end to the coronavirus pandemic, but he also warned Americans that the worst of the coronavirus assault — ’'maybe the toughest of this entire pandemic’'— remained ahead of them, despite early rounds of vaccinations underway....." 

I'm so sick of being threatened with this f**king hoax, even with a possible bioweapon variant out there.

The directly below co-lead:


The Wa$hington Compo$t says FTI Consulting is looking for anomalies among a variety of property deals, and will advise the district attorney on whether the president’s company manipulated the value of certain assets to obtain favorable interest rates and tax breaks.

I don't see any jail time there, do you?

The briefs:


Here is something even more earth-shaking:

"The United States sold the ambassador’s residence in Israel for more than $67 million in July, according to an official Israeli record of the sale that shines new light on a transaction that has been shrouded in secrecy. The State Department confirmed the sale in September but refused to identify the buyer or disclose the sale price of the sprawling beachfront compound in the upscale Tel Aviv suburb of Herzliya. On Tuesday, it said the sale had been “open and transparent.” The Israeli business newspaper Globes has identified the buyer as the U.S. casino magnate Sheldon Adelson, a strong supporter of both President Donald Trump and Israeli Prime Minister Benjamin Netanyahu. A representative of Adelson said the billionaire had no comment. Congressional aides told The Associated Press in September that lawmakers in the House and Senate were looking into whether the sale of the residence complied with regulations. The sale helped to cement Trump’s controversial decision to relocate the U.S. Embassy from Tel Aviv to contested Jerusalem in 2018 and to recognize Jerusalem as Israel’s capital. By selling the residence, it would make it harder for future presidents to reverse the decision to move the embassy..... "

Yeah, President-elect Biden has criticized the decision to move the embassy to Jerusalem but says he will not reverse it, and the symbolism regarding Adelson's hold on American politics (cheated out by the unholy and criminal Democratic trinity and Deep $tate) can't be immunized or walked back (btw, the Israelis gave the Palestinians in Gaza their usual holiday gift and did you see who will be his neighbor).

Meanwhile, a vote to legalize abortion in Argentina was balanced on a knife’s edge, according to the New York Times, before they plunged it in.


The New York Times said it more than doubled, but it was the exact same number in 2018.

Look, I'm sorry some of them lost their lives but considering all the death they have brought with their own lies, the self-serving whining for an occupational hazard has grown lame

{@@##$$%%^^&&}

Page A4 leads with the Globe's Political Notebook:


The Wa$hington Compo$t says he did not single out any Republican leaders by name, but Senate majority leader Mitch McConnell, Republican of Kentucky, appeared to be among those he was targeting.


It's Biden’s, not Trump’s.


Who would want to ruin Christmas in such a way?


Seasonal flu, 'er, COVID is its first big test as safety net, according to the New York Times, despite being around the past ten years during cold a flu season.

COVID-19 has never been isolated, folks, and now we are told it has mutated like all coronaviruses.

I'm sick of the slop they constantly serve out these days, sorry.


The article by Katie Benner of the New York Times, says:

"The orchestrated farewell was a reflection of how Barr navigated his tenure running a Justice Department for a president who viewed it as hostile toward him, but Barr also showed flashes of autonomy at the end of his tenure. His reversal on voter fraud broke from the president. He said he saw no need for a special counsel to investigate President-elect Joe Biden’s son Hunter as Trump clamored for one, and Barr even acknowledged that some of his suspicions about the Obama administration’s examination of Russian election interference were misguided. Historians will debate whether Barr, 70, was trying to preserve his reputation. Already a polarizing figure, he had faced a new groundswell of criticism in recent weeks for easing restrictions on election-related investigations as Trump ramped up his complaints about voting irregularities and for ensuring that the department’s examination of the Russia investigation continues into the Biden administration. Barr’s allies say he simply followed his instincts, honed by his maximalist view of executive power, and was untroubled by perceptions that he was serving Trump’s personal agenda. Either way, an examination of Barr’s tenure, based on interviews with allies, critics, current and former law enforcement officials, and academics shows that no matter what Barr says or does, Trump will ultimately define his legacy as attorney general....."


He has been left targeting voting by mail as a federal judge in Arizona blasted his fraud claim and the high court all but ended his long-shot legal efforts to overturn election, according to Adam Liptak of the The New York Times. He expected to prevail after rushing the confirmation of Justice Amy Coney Barrett in October, but was roundly rejected by all but Thomas and Alito.

They ruled against him in Wisconsin and in Alaska and basically killed his chances even after thousands of supporters returned to Washington for rallies to back his desperate efforts to subvert the election that he lost to Joe Biden and cheered for him as he flew overhead on his way out of town for the Army-Navy football game -- an event that was reminiscent of cross burnings!!

The long-shot effort is in the hands of Pence after the electoral college vote from an election that was as clean as a whistle (we all knew who was going to win Massachusetts) and that affirmed Biden as victor with leading Republicans calling him president-elect for the first time, essentially abandoning Trump’s assault on the outcome after the electoral college vote in a bid to counter Trump’s attempts to overturn the results with false claims that the election results are somehow in doubt.

So what is Trump’s endgame, or does he just retire to Mar-a-Lago?

The intrigue borders on the ridiculous, as he has plenty of cash in the bank. I wouldn't be surprised if he ended up back on TV with some high-profile gig or monument erected to himself after weighing naming an election conspiracy theorist as a special counsel (a consideration that sent shock waves through the president’s circle). He's already channeling Grover Cleveland, according to theWa$hington Compo$t, in a long-shot effort to reverse Biden’s victory and block the transition but then again, he is no Lincoln, either.

The Globe says Trump attorneys must face disciplinary action for the baseless lawsuits sabotaging Americans’ faith in the election system and in democracy itself (remember Conyers thundering at Rove during Attorneygate?) as Joe Kennedy delivered his farewell speech on House floor and hopes to follow in his granduncle's footsteps and fill those shoes and maybe even run for president someday -- something that Louisiana congressman-elect Luke Letlow will never be able to do, and oddly enough, the newly elected N.H. Speaker of the House died unexpectedly from, you guessed it, COVID-19.

{@@##$$%%^^&&}

Page A5:


The Wa$hington Compo$t says "the United States has invested billions of dollars in Somalia over the past decade, in part to build and train Danab, the only effective, apolitical fighting unit in the country’s war against Al Qaeda-affiliated Al Shabab. Now, with hundreds of the US troops who trained them leaving Somalia under orders from the Trump administration, current and former Danab officers are fearful that diminished American supervision will leave the elite division vulnerable to political interference from Somalia’s government, which is embroiled in a bitterly disputed election scheduled for February. Somalia continues to weather thousands of Al Shabab attacks big and small every year. While the US military ramped up a drone campaign in recent years — which it says will continue despite troops being ’'repositioned’' to neighboring Kenya and Djibouti and allegations that the campaign has killed dozens of civilians — Al Shabab still controls the majority of Somalia’s rural interior and runs an extensive tax racket that keeps it well funded....."

For those not in the know, the proper spelling and pronunciation is Al-CIA-Duh and Al-CIA-Bob.


The AP says the new accusations are a sign of Putin’s despair (ha-ha-ha), and they claim there was a secret Russian spy unit with expertise in poisonous substances trailing him and near when he was poisoned, with one official even confessing to a plot to poison him, according to Anton Troianovski of the New York Times, a top associate of Navalny in what echoes the Skripal fiasco from a few years back.

{@@##$$%%^^&&}

Page A8: 

"The first reported US case of the COVID-19 variant that’s been seen in the United Kingdom has been discovered in Colorado, Governor Jared Polis said Tuesday. It was found in a man in his 20s who is in isolation near Denver and has no travel history, state health officials said. Scientists in the United Kingdom believe the variant is more contagious than previous strains of SARS-CoV-2. The vaccines being given now are thought to be effective against the variant, Colorado officials said. Public health officials are investigating other potential cases and tracing contacts to gauge the spread of the variant in Colorado. “There is a lot we don’t know . . . but scientists in the United Kingdom are warning the world that it is significantly more contagious,” Polis noted. “The health and safety of Coloradans is our top priority.” Polis and state health officials were expected to address the public Wednesday. The discovery of the variant lead the CDC to issue new rules on Christmas Day for travelers arriving from the United Kingdom, requiring them to show proof of a negative COVID-19 test." 

As per the script, and no word on weather it is more deadly or just season flu.

Nevertheless, the travel restrictions are being implemented.

"The Centers for Disease Control and Prevention predicts the United States will see 400,000 coronavirus deaths by Jan. 20, the day President Trump is to leave office. The country surpassed 100,000 deaths in May and 200,000 four months later. It passed 300,000 in three months, and 400,000 looks set to take just one month, the CDC determined, using a collection of mathematical models. The United States has one of the highest mortality ratios, behind only Italy, Spain, and the United Kingdom. The predicted pace would mean an additional 65,000 deaths in coming weeks. The numbers are a reminder of the increasing speed with which the virus claims lives, underscoring the urgency of vaccination efforts. Weekly deaths are predicted to rise through Jan. 16, even though national case numbers have been falling for two weeks amid patchy holiday reporting....."

Well, there were supposed to be 2 MILLION dead Americans by now according to the damn models that shut us down, and only 6% of those deaths are COVID specific.


{@@##$$%%^^&&}

Page A12:

"The coronavirus pandemic might not be the ’'big one’' that experts have long feared, a World Health Organization official warned Tuesday during the global health agency’s last virtual media briefing of the year. Since the first reports of the novel coronavirus began circulating nearly a year ago, the WHO has repeatedly warned that the world must prepare for even deadlier pandemics in the future. ’'This pandemic has been very severe,’' WHO emergencies chief Mark Ryan said. ’'It has affected every corner of this planet, but this is not necessarily the big one.’' The coronavirus, he said, should serve as a ’'wake-up call.’' ’'These threats will continue,’' he said. ’'One thing we need to take from this pandemic, with all of the tragedy and loss, is we need to get our act together. We need to honor those we’ve lost by getting better at what we do every day.’' After the novel coronavirus emerged in China late last year, 2020 is coming to an end amid the rollout of new coronavirus vaccines. Case numbers are rising in some places, public health experts are warning about a highly transmissible variant of the virus first detected in the United Kingdom in September and since documented in more than 20 countries. While the variant does not appear to be more deadly or vaccine-resistant, it does transmit faster and is probably fueling outbreaks from England to South Africa. On Tuesday, German health officials said they detected a case of the UK variant dating back as early as November. An elderly coronavirus patient who had the variant ultimately died of the virus. The patient’s daughter had returned from Britain in mid-November, and the man’s wife was also infected with COVID-19, the illness the novel coronavirus can cause, but she survived, Agence France-Presse reported. Germany is one of several countries to temporarily bar travelers from the United Kingdom to prevent the variant’s spread. Much of England is under a lockdown. India on Tuesday confirmed its first cases of the UK variant after finding it in six people who had recently arrived from Britain. Indian Civil Aviation Minister Hardeep Singh Puri told reporters Tuesday that the country probably would issue a temporary ban on flights from the United Kingdom as a result. Countries across Europe, Asia, and the Middle East have documented cases of the fast-spreading form of the virus. Canada on Saturday was the first to report it in North America. It is probably already circulating undetected in the United States, according to public health experts. The United States has the world’s highest count of coronavirus infections and fatalities (Washington Post)." 

Is it not interesting and somewhat coincidental that the variant is showing up where they are vaccinating first? 

What if the VARIANT is IN the VACCINE?!

I'll tell you this, it wouldn't be the first time.

Btw, Russia is no help:

"After months of questions over the true scale of the coronavirus pandemic in Russia and the efficacy of a Russian-developed vaccine, the state statistical agency in Moscow has announced new figures indicating that the death toll from COVID-19 is more than three times as high as officially reported. Russia has reported more than 3 million cases of infection, making it the world’s fourth-hardest-hit country, but only 55,827 deaths, fewer than in seven other countries. A demographer at a government agency who questioned the official fatality figures, dismissing them as far too low, was fired over the summer. New data issued Monday by Rosstat, the state statistics agency, however, indicated that the demographer was right and the real number of fatalities is far higher than previously reported. The agency reported that the number of deaths between January and November was 229,732 higher than over the same period last year, an increase that a senior official blamed largely on the coronavirus. Tatyana Golikova, a deputy prime minister leading Russia’s efforts to combat the pandemic, told a government briefing Monday that more than 81 percent of the increased number of deaths in 2020 was “due to COVID,” which would mean that the virus had killed more than 186,000 Russians so far this year. This is still far fewer than the more than 334,000 deaths caused by COVID-19 in the United States but means that Russia has suffered more fatalities as a result of the pandemic than European countries like Italy, France, and Britain, whose poor record has been regularly cited by Russian state media as proof of Russia’s relative triumph. As of Tuesday afternoon, the webpage giving Rosstat’s new data was inaccessible. The gap between the official death rate and the real one is largely explained by Russia’s practice of recording a death as coronavirus-related only in cases where an autopsy has confirmed the coronavirus as the main cause. Critics say this has allowed authorities to massage the numbers. Russia in August became the first country to register a coronavirus vaccine, but a recent survey found that only 38 percent of Russians intend to get vaccinated (New York Times)." 

The exact opposite is the truth, the numbers have been vastly overinflated, and the New York Times projection regarding the numbers is sickening.


That is when the Spanish flu got rolling 100 years ago, AFTER the VACCINATIONS!!